US 11,980,669 B2
Capped and uncapped antibody cysteines, and their use in antibody-drug conjugation
Xiaotian Zhong, Wayland, MA (US); Amarnauth Shastrie Prashad, New City, NY (US); Ronald William Kriz, Northborough, MA (US); Tao He, Acton, MA (US); Will Somers, Lexington, MA (US); Wenge Wang, Andover, MA (US); and Leo Joseph Letendre, Oakdale, CT (US)
Assigned to Pfizer, Inc., New York, NY (US)
Filed by PFIZER INC., New York, NY (US)
Filed on Mar. 3, 2020, as Appl. No. 16/807,375.
Application 16/807,375 is a division of application No. 15/748,268, granted, now 10,653,794, previously published as PCT/IB2016/054789, filed on Aug. 9, 2016.
Claims priority of provisional application 62/204,005, filed on Aug. 12, 2015.
Prior Publication US 2020/0230256 A1, Jul. 23, 2020
Int. Cl. A61K 47/68 (2017.01); A61K 38/05 (2006.01); A61K 38/50 (2006.01); C07K 16/00 (2006.01); C07K 16/30 (2006.01)
CPC A61K 47/6889 (2017.08) [A61K 38/05 (2013.01); A61K 47/68 (2017.08); A61K 47/6817 (2017.08); A61K 47/6851 (2017.08); A61K 47/6855 (2017.08); C07K 16/00 (2013.01); C07K 16/30 (2013.01); C07K 2317/14 (2013.01); C07K 2317/40 (2013.01); C07K 2317/526 (2013.01); C07K 2317/55 (2013.01); C07K 2317/94 (2013.01)] 5 Claims
 
1. A method of producing a labeled antibody, said method comprising
producing a labeled antibody in a cell culture, wherein at least one covalent sulfur-containing bond is formed by reaction of an exposed thiol group from at least one unpaired cysteine residue on the Fc region of said antibody with at least one predetermined capping moiety,
wherein said at least one predetermined capping moiety is selected from the group consisting of: maleimido trioxa-4-formyl benzamide (MTFB), dibenzocyclooctyl-polyethylene maleimide (DBCO-PEG4-Maleimide), maleimide-PEG2-Biotin (MPB), and azido-PEG3-maleimide.